Targeting cellular cathepsins inhibits hepatitis E virus entry.
Mara KlöhnThomas BurkardJuliana JanzenJil Alexandra SchraderAndré GömerRebecca FuGeorge Liam SsebyatikaMaximilian K NockeRichard J P BrownThomas KreyViet Loan Dao ThiVolker KinastYannick BrüggemannDaniel TodtEike SteinmannPublished in: Hepatology (Baltimore, Md.) (2024)
In summary, our study highlights the pivotal role of lysosomal cathepsins, especially CTSL, in the HEV entry process. The profound anti-HEV efficacy of the pan-cathepsin inhibitor K11777, especially with its notable safety profile in primary cells, further underscores its potential as a therapeutic candidate.